IMPEL NEUROPHARMA, INC.
Precision Olfactory Delivery (POD) device for non-invasive nose-to-brain drug delivery to bypass the blood-brain barrier
- Sector
- Medtech
- Headquarters
- SEATTLE, WA
- Founded
- 2008
- Latest Form D
- $1.9M offered, Apr 2021
- Total capital
- $42.7M
- Federal grants
- $3M
- 3 awards · 2016–2017
- Rank in peer group#357 of 538
- Private capital raised
- $39.7M
- 16 Form D · last Apr 2021
- 67 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 29 pending · first 2017
- Rank in peer group#61 of 538
Capital timeline
Latest events
- Offering registeredForm D · SEC · 16th filing$1.9M
- Private capital raisedForm D · SEC · 15th filing$7.5M
- Offering registeredForm D · SEC · 14th filing$490K
- Offering registeredForm D · SEC · 13th filing$5.6M
- Offering registeredForm D · SEC · 12th filing$481K
- Offering registeredForm D · SEC · 11th filing$1.6M
- Offering registeredForm D · SEC · 10th filing$1.4M
- Private capital raisedForm D · SEC · 9th filing$22.3M
- Private capital raisedForm D · SEC · 8th filing$80K
- Private capital raisedForm D · SEC · 7th filing$1.1M
- Private capital raisedForm D · SEC · 6th filing$4M
- Private capital raisedForm D · SEC · 5th filing$1.3M
- Private capital raisedForm D · SEC · 4th filing$2.6M
- Private capital raisedForm D · SEC · 3rd filing$25K
- Private capital raisedForm D · SEC · 2nd filing$527K
- Private capital raisedForm D · SEC · 1st filing$305K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Tool for non-invasive delivery of central nervous system drug candidates$574K
- Federal grantHealth and Human S · Phase II · Tool for non invasive delivery of central nervous system drug candidates$1.5M
- Federal grantHealth and Human S · Phase II · Tool for non-invasive delivery of central nervous system drug candidates$914K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grantsBelow median
- Granted patents#61 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- John D. HoekmanResearcherExecutive Officer, DirectorLinked by 4 patents · $3M in grants as PI
- Aaron D. RoystonDirectorNamed in SEC Form D filings
- Adrian D. AdamsExecutive Officer, DirectorNamed in SEC Form D filings
- Ali D. SatvatDirectorNamed in SEC Form D filings
- David D. AllisonDirectorNamed in SEC Form D filings
- Diane D. WilfongDirectorNamed in SEC Form D filings
Show all 15 people
- Jim D. YoungDirectorNamed in SEC Form D filings
- John D. LeamanExecutive OfficerNamed in SEC Form D filings
- Jon D. CongletonExecutive Officer, DirectorNamed in SEC Form D filings
- Mahendra D. ShahDirectorNamed in SEC Form D filings
- Michael P. HiteExecutive Officer, DirectorNamed in SEC Form D filings
- Robert D. MittendorffDirectorNamed in SEC Form D filings
- Rodney D. HoDirectorNamed in SEC Form D filings
- Stewart D. ParkerDirectorNamed in SEC Form D filings
- Tim D. NelsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 39- GrantedIntranasal Delivery Of Olanzapine By Precision Olfactory DeviceUSPTOUS 11,278,492
- GrantedIn-line Nasal Delivery DeviceUSPTOUS 11,266,799
- GrantedMedical Unit Dose ContainerUSPTOUS 11,191,910
Show all 39 patent records
- Intranasal Delivery Of Olanzapine By Precision Olfactory DeviceMar 22, 2022 · US 11,278,492Granted
- In-line Nasal Delivery DeviceMar 8, 2022 · US 11,266,799Granted
- Medical Unit Dose ContainerDec 7, 2021 · US 11,191,910Granted
- Intranasal Delivery Of Dihydroergotamine By Precision Olfactory DeviceNov 30, 2021 · US 11,185,497Granted
- Nozzles For Nasal Drug DeliveryMay 18, 2021 · US 11,007,332Granted
- Nozzles for Nasal Drug DeliveryMar 9, 2021 · US 10,940,278Granted
- Medical Unit Dose ContainerJan 21, 2020 · US 10,537,692Granted
- Nasal Drug Delivery DeviceDec 17, 2019 · US 10,507,295Granted
- Intranasal Delivery Of Dihydroergotamine By Precision Olfactory DeviceJul 11, 2019 · Application 16240639Pending
- Nozzles For Nasal Drug DeliveryMar 20, 2018 · US 9,919,117Granted
- Nasal Drug Delivery DeviceJan 24, 2017 · US 9,550,036Granted
- Muroid Family Nasal DeviceApr 9, 2015 · Application 14508701Pending
- Intranasal Delivery Of Olanzapine By Precision Olfactory DeviceApplication 62776414Pending
- Intranasal Delivery Of Olanzapine By Precision Olfactory DeviceApplication 62774088Pending
- Intranasal Device With Inlet InterfaceApplication PCTUS2018062280Pending
- Intranasal Device With Dip TubeApplication PCTUS2018062296Pending
- Respiratory Tract Delivery Of Levodopa And Dopa Decarboxylase Inhibitor For Treatment Of Parkinson's DiseaseApplication 62700584Pending
- Intranasal Delivery Of Levodopa Powder By Precision Olfactory DeviceApplication 62700591Pending
- Intranasal Delivery Of Dihydroergotamine By Precision Olfactory DeviceApplication 62643657Pending
- Intranasal Delivery Of Dihydroergotamine By Precision Olfactory DeviceApplication 62613939Pending
- Intranasal Delivery Of Levodopa Powder By Precision Olfactory DeviceApplication 62614310Pending
- Intranasal Delivery Of Olanzapine By Precision Olfactory DeviceApplication 62614324Pending
- Intranasal Device With Inlet InterfaceApplication 62589326Pending
- Dip Tube DeviceApplication 62589306Pending
- In-line Nasal Delivery DeviceApplication PCTUS2016051169Pending
- In Line Nasal Delivery DeviceApplication 62216789Pending
- Unit Dose ContainerApplication PCTUS2014035711Pending
- Nasal Drug Delivery DeviceApplication PCTUS2012027754Pending
- Single-use Nasal Delivery DeviceApplication PCTUS2020033282Pending
- Repeated Administration Of Dihydroergotamine For Treatment Of Frequent Migraine HeadachesApplication 62961076Pending
- Nasal Drug Delivery DeviceApplication PCTUS2019066921Pending
- Respiratory Tract Delivery Of Levodopa And Dopa Decarboxylase Inhibitors For Treatment Of Parkinson's DiseaseApplication PCTUS2019042689Pending
- Single-use Nasal Delivery DeviceApplication 62849735Pending
- Respiratory Tract Delivery Of Levodopa And Dopa Decarboxylase Inhibitor For Treatment Of Parkinson's DiseaseApplication 62820244Pending
- Intranasal Delivery Of Levodopa Power By Precision Olfactory DeviceApplication PCTUS2019012424Pending
- Intranasal Delivery Of Olanzapine By Precision Olfactory DeviceApplication PCTUS2019012426Pending
- Intranasal Delivery Of Dihydroergotamine By Precision Olfactory DeviceApplication PCTUS2019012405Pending
- Intranasal Delivery Of Levodopa Powder By Precision Olfactory DeviceApplication 16240642Pending
- Nasal Drug Delivery DeviceApplication 62788093Pending
Related companies, and why
- MEMStim LLCSimilar federal contract value in Medtech · null in contracts
- BIOINVISION INCSimilar federal contract value in Medtech · null in contracts
- SYNCHROHEALTH LLCSimilar federal contract value in Medtech · null in contracts
- CYTOSITE BIOPHARMA, INC.Similar federal contract value in Medtech · null in contracts
- PHOEBUS OPTOELECTRONICS LLCSimilar federal contract value in Medtech · null in contracts
- LDS TECHNOLOGY CONSULTANTS INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .